SEC Filing Details

We are a clinical-stage biopharmaceutical company leveraging our proprietary next-generation, non-viral gene engineering technologies to create life-saving cell and gene therapies for patients with high unmet medical need.

SEC Filing Details

Document Details

Filing Date
Aug 10, 2020
Document Date
Aug 10, 2020
Form Description
A statement of beneficial ownership of common stock by certain persons
Filing Group
Other
Company
Poseida Therapeutics, Inc.
Issuer
Poseida Therapeutics, Inc.